Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX)

37 filings reported holding RNTX - Rein Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2024.
Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5.68M shares of 23.6M outstanding shares and own 24.07% of the company stock.
Largest 10 shareholders include BIOS Capital Management, LP (1.69M shares), Voss Capital, LP (956K shares), UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO (617K shares), VANGUARD GROUP INC (425K shares), Cable Car Capital, LP (420K shares), Prosight Management, LP (405K shares), GEODE CAPITAL MANAGEMENT, LLC (241K shares), Sigma Planning Corp (236K shares), Senvest Management, LLC (231K shares), and Royal Bank of Canada (107K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.